Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Rohrbeck, Astrid ^a   Borlak, Jürgen ^a,b  

^a FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; DNA GLYCOSYLTRANSFERASE; EPIREGULIN; GUANINE; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; RAF PROTEIN; TYROSINE KINASE RECEPTOR; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; WNT PROTEIN;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENETICS; CANCER GROWTH; CELL ADHESION; CELL POPULATION; CONTROLLED STUDY; ENZYME ACTIVATION; GAP JUNCTION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC CODE; GENOMICS; LASER MICRODISSECTION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; LUNG DYSPLASIA; LUNG ENDOTHELIUM; MALIGNANT TRANSFORMATION; MESENCHYME CELL; MOUSE; NONHUMAN; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SOLID TUMOR; TIGHT JUNCTION; TRANSGENIC MOUSE; UPREGULATION; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; CELL TRANSFORMATION; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN; HUMAN GENOME; LUNG TUMOR; METABOLISM; PRINCIPAL COMPONENT ANALYSIS;

MUS MUSCULUS;

ADENOCARCINOMA; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENOME, HUMAN; GENOMICS; HUMANS; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; PRINCIPAL COMPONENT ANALYSIS; PROTO-ONCOGENE PROTEINS C-RAF;

EID: 70350603057     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007315     Document Type: Article

References (228)

1. Rom WN, Hay JG, Lee TC, Jiang Y, Tchou-Wong KM (2000) Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med 161: 1355-67.
2. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898.
3. Denissenko MF, Pao A, Tang M, Pfeifer GP (1996) Preferential formation of benzo [a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274: 430-2.
4. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, et al. (1998) Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. PNAS 95: 11891-6.
5. Hunter T, Pines J (1994) Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-82.
6. Thomas RK, Weir B, Meyerson M (2006) Genomic Approaches to Lung Cancer. Clin Cancer Res 12: 4384s-4391s.
7. Rachwal WJ, Bongiorno PF, Orringer MB, Whyte RI, Ethier SP, et al. (1995) Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br J Cancer 72: 56-64.
8. Rohrbeck A, Müller VS, Borlak J (2009) Molecular characterization of lung dysplasia induced by c-raf-1. PLoSONE 4(5): e5637.
9. Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T, et al. (2000) Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ 11: 185-90.
10. Cekanova M, Majidy M, Masi T, Al-Wadei HAN, Schuller HM (2007) Overexpressed Raf-1 and phosphorylated cyclic adenosine 3′-5′- monophosphatate response element-binding protein are early markers for lung adenocarcinoma. Cancer 109: 1164-73.
11. Lamberti A, Longo O, Marra M, Tagliaferri P, Bismuto E, et al. (2007) C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death Differ 14: 952-62.
12. Baccarini M (2005) Second nature: Biological functions of Raf-1 "kinase". FEBS Lett 579: 3271-3277.
13. Manenti G, Peissel B, Gariboldi M, Falvella FS, Zaffaroni D, et al. (2000) A cancer modifier role for parathyroid hormone-related protein. Oncogene 19: 5324-8.
14. Rabbani SA (2000) Molecular mechanism of action of parathyroid hormone related peptide in hypercalcemia of malignancy: therapeutic strategies (review). Int J Oncol 16: 197-206.
15. Centrella M, Canalis E, McCarthy TL, Stewart AF, Orloff JJ, et al. (1989) Parathyroid hormone-related protein modulates the effect of transforming growth factor-beta on deoxyribonucleic acid and collagen synthesis in fetal rat bone cells. Endocrinology 125: 199-208.
16. Burton PB, Moniz C, Knight DE (1990) Parathyroid hormone related peptide can function as an autocrine growth factor in human renal cell carcinoma. Biochem Biophys Res Commun 167: 1134-8.
17. Iwamura M, Abrahamsson PA, Foss KA, Wu G, Cockett AT, et al. (1994) Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 43: 675-9.
18. Takai E, Yano T, Iguchi H, Fukuyama Y, Yokoyama H, et al. (1996) Tumor-induced hypercalcemia and parathyroid hormone-related protein in lung carcinoma. Cancer 78: 1384-7.
19. Burton PB, Knight DE (1992) Parathyroid hormone-related peptide can regulate the growth of human lung cancer cells, and may form part of an autocrine TGF-alpha loop. FEBS Lett 305: 228-32.
20. Clyde-Smith J, Silins G, Gartside M, Grimmond S, Etheridge M, et al. (2000) Characterization of RasGRP2, a plasma membrane-targeted, dual specificity Ras/Rap exchange factor. J Biol Chem 275: 32260-7.
21. Anborgh PH, Qian X, Papageorge AG, Vass WC, DeClue JE (1999) Ras-specific exchange factor GRF: oligomerization through its Dbl homology domain and calcium-dependent activation of Raf. Mol Cell Biol 19: 4611-22.
22. Birkenfeld J, Nalbant P, Yoon SH, Bokoch GM (2008) Cellular functions of GEF-H1, a microtubule-regulated Rho-GEF: is altered GEF-H1 activity a crucial determinant of disease pathogenesis? Trends Cell Biol 18: 210-9.
23. Wodarz A, Nusse R (1998) Mechanisms of wnt signalling in development. Annu Rev Cell Dev Biol 14: 59-88.
24. Polakis P (2000) Wnt signaling and cancer. Genes Dev 14: 1837-51.
25. Pongracz JE, Stockley RA (2006) Wnt signalling in lung development and diseases. Respir Res 7: 15.
26. Eberhart CG, Argani P (2001) Wnt signaling in human development: beta-catenin nuclear translocation in fetal lung, kidney, placenta, capillaries, adrenal, and cartilage. Pediatr Dev Pathol 4: 351-7.
27. Mucenski ML, Wert SE, Nation JM, Loudy DE, Huelsken J, et al. (2003) beta-Catenin is required for specification of proximal/distal cell fate during lung morphogenesis. J Biol Chem 278: 40231-8.
28. Smythe WR, Williams JP, Wheelock MJ, Johnson KR, Kaiser LR, et al. (1999) Cadherin and catenin expression in normal human bronchial epithelium and non-small cell lung cancer. Lung Cancer 24: 157-168.
29. Woenckhaus M, Klein-Hitpass L, Grepmeier U, Merk J, Pfeifer M, et al. (2006) Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers. J Pathol 210: 192-204.
30. Pirinen RT, Hirvikoski P, Johansson RT, Hollmen S, Kosma VM (2001) Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol 54: 391-395.
31. Ju Z, Kapoor M, Newton K, Cheon K, Ramaswamy A, et al. (2005) Global detection of molecular changes reveals concurrent alteration of several biological pathways in nonsmall cell lung cancer cells. Mol Genet Genomics 274: 141-154.
32. Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, et al. (2005) Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor-an expression in non-small-cell lung cancer. Journal of Clinical Oncology 23: 8765-8773.
33. You L, He B, Xu Z, Uematsu K, Mazieres J, et al. (2004) Inhibition of Wnt2 mediated signaling induces programmed cell death in non-small cell lung cancer cells. Oncogene 23: 6170-4.
34. Quaggin SE, Schwartz L, Cui S, Igarashi P, Deimling J, et al. (1999) The basic helix-loop-helix protein Pod1 is critically important for kidney and lung organogenesis. Development 126: 5771-83.
35. Smith LT, Lin M, Brena RM, Lang JC, Schuller DE, et al. (2006) Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. PNAS 103: 982-7.
36. Uyttendaele H, Marazzi G, Wu G, Yan Q, Sassoon D, et al. (1996) Notch4/ int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development 122: 2251-9.
37. Taylor KL, Henderson AM, Hughes CC (2002) Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Microvascular Research 64: 372-383.
38. Baron M (2003) An overview of the Notch signalling pathway. Seminars in Cell & Developmental Biology 14: 113-119.
39. Soriano JV, Uyttendaele H, Kitajewski J, Montesano R (2000) Expression of an activated Notch4(int-3) oncoprotein disrupts morphogenesis and induces an invasive phenotype in mammary epithelial cells in vitro. Int J Cancer 86: 652-9.
40. Nickoloff BJ, Osborne BA, Miele L (2003) Notch signalling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22: 6598-608.
41. Gramantieri L, Giovannini C, Lanzi A, Chieco P, Ravaioli M, et al. (2007) Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int 27: 997-1007.
42. Frints SGM, Marynen P, Hartmann D, Fryns JP, Steyaert J, et al. (2003) CALL interrupted in a patient with non-specific mental retardation: gene dosage-dependent alteration of murine brain development and behavior. Hum Molec Genet 12: 1463-1474.
43. Schlatter MC, Buhusi M, Wright AG, Maness PF (2008) CHL1 promotes Sema3A-induced growth cone collapse and neurite elaboration through a motif required for recruitment of ERM proteins to the plasma membrane. J Neurochem 104: 731-44.
44. Di Sciullo G, Donahue T, Schachner M, Bogen SA (1998) L1 antibodies block lymph node fibroblastic reticular matrix remodeling in vivo. J Exp Med 187: 1953-63.
45. Debiec H, Christensen EI, Ronco PM (1998) The cell adhesion molecule L1 is developmentally regulated in the renal epithelium and is involved in kidney branching morphogenesis. J Cell Biol 143: 2067-79.
46. Nolte C, Moos M, Schachner M (1999) Immunolocalization of the neural cell adhesion molecule L1 in epithelia of rodents. Cell Tissue Res 298: 261-73.
47. Izumoto S, Ohnishi T, Arita N, Hiraga S, Taki T, et al. (1996) Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion. Cancer Res 56: 1440-4.
48. Thies A, Schachner M, Moll I, Berger J, Schulze HJ, et al. (2002) Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer 38: 1708-16.
49. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, et al. (2003) L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 362: 869-75.
50. Schmid RS, Maness PF (2008) L1 and NCAM adhesion molecules as signaling coreceptors in neuronal migration and process outgrowth. Curr Opin Neurobiol 18: 1-6.
51. Somersalo K, Carpen O, Saksela E, Gahmberg CG, Nortamo P, et al. (1995) Activation of natural killer cell migration by leukocyte integrin-binding peptide from intracellular adhesion molecule-2 (ICAM-2). J Biol Chem 270: 8629-36.
52. Staunton DE, Dustin ML, Springer TA (1989) Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 339: 61-4.
53. Bretscher A (1999) Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol 11: 109-16.
54. Tanaka H, Yashiro M, Sunami T, Sakate Y, Kosaka K, et al. (2004) ICAM-2 gene therapy for peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res 10: 4885-92.
55. Lasky LA (1992) Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 258: 964-9. Review.
56. Smolen JE, Petersen TK, Koch C, O'Keefe SJ, Hanlon WA, et al. (2000) L-selectin signaling of neutrophil adhesion and degranulation involves p38 mitogen-activated protein kinase. J Biol Chem 275: 15876-15884.
57. Chen A, Engel P, Tedder TF (1995) Structural requirements regulate endoproteolytic release of the L-selectin (CD62L) adhesion receptor from the cell surface of leukocytes. J Exp Med 182: 519-30.
58. Tedder TF, Steeber DA, Chen A, Engel P (1995) The selectins: vascular adhesion molecules. FASEB J 9: 866-873.
59. Waddell TK, Fialkow L, Chan CK, Kishimoto TK, Downey GP (1995) Signaling functions of L-selectin. Enhancement of tyrosine phosphorylation and activation of MAP kinase. J Biol Chem 270: 15403-15411.
60. Cao G, O'Brien CD, Zhou Z, Sanders SM, Greenbaum JN, et al. (2002) Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. Am J Physiol Cell Physiol 282: C1181-90.
61. Matsumura T, Wolff K, Petzelbauer P (1997) Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin. J Immunol 158: 3408-16.
62. Navarro P, Ruco L, Dejana E (1998) Differential localization of VE- and N-cadherins in human endothelial cells: VE-cadherin competes with N-cadherin for junctional localization. J Cell Biol 140: 1475-84.
63. Huber O, Bierkamp C, Kemler R (1996) Cadherins and catenins in development. Curr Opin Cell Biol 8: 685-691.
64. Gumbiner BM (1996) Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 84: 345-357.
65. Gavard J, Gutkind S (2008) VE-cadherin and claudin-5:it takes two to tango. Nat Cell Biol 10: 883-885.
66. Taddei A, Giampietro C, Conti A, Orsenigo F, Breviario F, et al. (2008) Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol 10: 923-34.
67. Wang F, Daugherty B, Keise LL, Wei Z, Foley JP, et al. (2003) Heterogeneity of claudin expression by alveolar epithelial cells. Am J Respir Cell Mol Biol 29: 62-70.
68. Coyne CB, Gambling TM, Boucher RC, Carson JL, Johnson LG (2003) Role of claudin interactions in airway tight junctional permeability. Am J Physiol Lung Cell Mol Physiol 285: L1166-78.
69. Moldvay J, Jäckel M, Paska C, Solesz I, Schaff Z, et al. (2007) Distinct claudin expression profile in histologic subtypes of lung cancer. Lung Cancer 57: 159-67.
70. Miyamori H, Takino T, Kobayashi Y, Tokai H, Itoh Y, et al. (2001) Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. J Biol Chem 276: 28204-28211.
71. Bastide B, Neyses L, Ganten D, Paul M, Willecke K, et al. (1993) Gap junction protein connexin40 is preferentially expressed in vascular endothelium and conductive bundles of rat myocardium and is increased under hypertensive conditions. Circ Res 73: 1138-1149.
72. Isakson BE, Seedorf GJ, Lubman RL, Evans WH, Boitano S (2003) Cell-cell communication in heterocellular cultures of alveolar epithelial cells. Am J Respir Cell Mol Biol 29: 552-561.
73. Udaka N, Miyagi Y, Ito T (2007) Connexin expression in mouse lung tumor. Cancer Lett 246: 224-9. Epub 2006.
74. Berthoud VA, Minogue PJ, Laing JG, Beyer EC (2004) Pathways for degradation of connexins and gap junctions. Cardiovasc Res 62: 256-267.
75. Warn-Cramer BJ, Lau AF (2004) Regulation of gap junctions by tyrosine protein kinases. Biochim. Biophys Acta 1662: 81-95.
76. Toyoda H, Komurasaki T, Uchida D, Morimoto S (1997) Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem J 326: 69-75.
77. Lindvall C, Hou M, Komuraski T, Zheng C, Henriksson M, et al. (2003) Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res 63: 1743-7.
78. Katoh Y, Katoh M (2006) Canonical WNT signaling pathway and human AREG. Int J Mol Med 17: 1163-6.
79. Hurbin A, Dubrez L, Coll JL, Favrot MC (2002) Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines. JBC 277: 49127-49133.
80. Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-49.
81. Matakidou A, El Galta R, Rudd MF, Webb EL, Bridle H, et al. (2007) Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer 96: 1904-7.
82. Marks JL, McLellan MD, Zakowski MF, Lash AE, Kasai Y, et al. (2007) Mutational analysis of EGFR and related signaling pathway genes in lung Adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE 2: e426.
83. Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, et al. (2007) Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 67: 593-9.
84. Dome B, Timar J, Dobos J, Meszaros L, Raso E, et al. (2006) Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 66: 7341-7.
85. Doolittle RF, Hunkapiller MW, Hood LE, Devare SG, Robbins KC, et al. (1983) Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science 221: 275-277.
86. Waterfield MD, Scrace GT, Whittle N, Stroobant P, Johnsson A, et al. (1983) Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature 304: 35-39.
87. Heldin CH, Ostman A, Ronnstrand L (1998) Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1378: F79-F113.
88. Smits A, Funa K, Vassbotn FS, Beausang-Linder M, af Ekenstam F, et al. (1992) Expression of platelet-derived growth factor and its receptors in proliferative disorders of fibroblastic origin. Am J Pathol 140: 639-648.
89. Kikuchi K, Soma Y, Fujimoto M, Kadono T, Sato S, et al. (1993) Dermatofibrosarcoma protuberans: increased growth response to platelet-derived growth factor BB in cell culture. Biochem Biophys Res Commun 196: 409-415.
90. Simon MP, Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, et al. (1997) Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 15: 95-98.
91. Dirks RP, Jansen HJ, Onnekink C, De Jonge RJ, Bloemers HP (1993) DNase-I-hypersensitive sites located far upstream of the human c-sis/ PDGF-B gene comap with transcriptional enhancers and a silencer and are preceded by (part of) a new transcription unit. Eur J Biochem 216: 487-495.
92. Younes RN, Noguchi Y (2000) Pathophysiology of cancer cachexia. Rev Hosp Clín Fac Med S Paulo 55: 181-193.
93. Russel ST, Tisdale MJ (2002) Effect of a tumour-derived lipid-mobilising factor on glucose and lipid metabolism in vivo. Br J Cancer 87: 580-4.
94. Anggard E, Samuelsson B (1964) Metabolism of prostaglandin E, in guinea pig lung: the structure of two metabolites. J Biol Chem 239: 4097-4102.
95. Anggard E (1966) The biological activities of three metabolites of prostaglandin E. Acta Physiol 66: 509-5 I0.
96. Hansen H (1974) 15Hydroxyprostaglandin dehydrogenase. A review. Prostaglandins 12: 647-679.
97. Bergholte J, Soberman R, Hayes R, Murphy R, Okita R (1987) Oxidation of 15-hydroxyeicosatetraenoic acid and other hydroxyl fatty acids by prostaglandin dehydrogenase. Arch Biochem Biophys 257: 444-450.
98. Serhan CN, Fiore S, Brezinski DA, Lynch S (1993) Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: conversion to novel 15-0∼0 and dihydro products. Biochemistry 32: 6313-6319.
99. Ensor CM, Tai HH (1995) 15-Hydroxyprostaglandin dehydrogenase. J Lipid Mediat Cell Signal 12: 313-319.
100. Thomas GM, Cunningham E, Fensome A, Ball A, Totty NF, et al. (1993) An essential role for phosphatidylinositol transfer protein in phospholipase C-mediated inositol lipid signalling. Cell 74: 919-928.
101. Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C (2001) The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 155: 269-281.
102. Wolfbauer G, Albers JJ, Oram JF (1999) Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim Biophys Acta 1439: 65-76.
103. Oram JF, Wolfbauer G, Vaughan AM, Tang C, Albers JJ (2003) Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J Biol Chem 278: 52379-52385.
104. Hofmann K (2000) A superfamily of membrane-bound O-acyltransferases with implications for wnt signaling. Trends Biochem Sci 25: 111-2.
105. Hishikawa D, Shindou H, Kobayashi S, Nakanishi H, Taguchi R, et al. (2008) Discovery of a lysophospholipid acyltransferase family essential for membrane asymmetry and diversity. PNAS 105: 2830-2835.
106. Hilden JM, Smith FO, Frestedt JL, McGlennen R, Howells WB, et al. (1997) MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Blood 89: 3801-5.
107. George JN, Nurden AT, Phillips DR (1984) Molecular defects in interactions of platelets with the vessel wall. N Engl J Med 311: 1084.
108. Wu DF, Koch T, Liang YJ, Stumm R, Schulz S, et al. (2007) Membrane glycoprotein M6a interacts with the micro-opioid receptor and facilitates receptor endocytosis and recycling. J Biol Chem 282: 22239-47.
109. Eberhardt C, Gray PW, Tjoelker LW (1999) cDNA cloning, expression and chromosomal localization of two human lysophosphatidic acid acyltransferases. Adv Exp Med Biol 469: 351-.
110. Rieger S, Volkmann K, Köster RW (2008) Polysialyltransferase expression is linked to neuronal migration in the developing and adult zebrafish. Dev Dyn 237: 276-85.
111. Ruiz A, Winston A, Lim YH, Gilbert BA, Rando RR, et al. (1999) Molecular and biochemical characterization of lecithin retinol acyltransferase. J Biol Chem 274: 3834-41.
112. Esch FS, Shimasaki S, Mercado M, Cooksey K, Ling N, et al. (1987) Structural characterization of follistatin: a novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad. Mol Endocrinol 1: 849-55.
113. Nakamura T, Takio K, Eto Y, Shibai H, Titani K, et al. (1990) Activinbinding protein from rat ovary is follistatin. Science 247: 836-8.
114. Connolly DJ, Patel K, Seleiro EA, Wilkinson DG, Cooke J (1995) Cloning, sequencing, and expressional analysis of the chick homologue of follistatin. Dev Genet 17: 65-77.
115. Iemura S, Yamamoto TS, Takagi C, Uchiyama H, Natsume T, et al. (1998) Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci U S A 95: 9337-42.
116. Tardif G, Hum D, Pelletier JP, Boileau C, Ranger P, et al. (2004) Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis Rheum 50: 2521-2530.
117. Lories RJ, Luyten FP (2005) Bone morphogenetic protein signaling in joint homeostasis and disease. Cytokine Growth Factor Rev 16: 287-298.
118. Grusch M, Drucker C, Peter-Vörösmarty B, Erlach N, Lackner A, et al. (2006) Deregulation of the activin/follistatin system in hepatocarcinogenesis. J Hepatol 45: 673-80.
119. Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M (2008) AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 8: 200.
120. Kang W, Saqui-Salces M, Zavros Y, Mechant JL (2008) Induction of follistatin precedes gastric transformation in gastrin deficient mice. Biochem Biophys Res Commun.
121. Graham A, Papalopulu N, Krumlauf R (1989) The murine and Drosophila homeobox gene complexes have common features of organization and expression. Cell 57: 367-378.
122. Walsh CM, Carroll SB (2007) Collaboration between Smads and a Hox protein in target gene repression. Development 134: 3585-3592.
123. Packer AI, Mailutha KG, Ambrozewicz LA, Wolgemuth DJ (2000) Regulation of the HoxA4 and HoxA5 genes in the embryonic mouse lung by retinoic acid and TGFbeta1: implications for lung development and patterning. Dev Dyn 217: 62-74.
124. Volpe MV, Vosatka RJ, Nielsen HC (2000) HoxB5-5 control of early airway formation during branching morphogenesis in the developing mouse lung. Biochim Biophys Acta 1475: 337-345.
125. Hershko AY, Kafri T, Fainsod A, Razin A (2003) Methylation of HoxA5 and HoxB5 and its relevance to expression during mouse development. Gene 302: 65-72.
126. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, et al. (2007) Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci U S A 104(13): 5527-32.
127. Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF, et al. (2000) Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405: 974-978.
128. Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res 13: 5048-55.
129. Wu Q, Lothe RA, Ahlquist T, Silins I, Trope CG, et al. (2007) DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer 6: 45.
130. Moskow JJ, Bullrich F, Huebner K, Daar IO, Buchberg AM (1995) Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. Mol Cell Biol 15: 5434-5443.
131. Shanmugam K, Green NC, Rambaldi I, Saragovi HU, Featherstone MS (1999) PBX and MEIS as non-DNA-binding partners in trimeric complexes with HOX proteins. Mol Cell Biol 19: 7577-7588.
132. Crijns AP, de Graeff P, Geerts D, Ten Hoor KA, Hollema H, et al. (2007) MEIS and PBX homeobox proteins in ovarian cancer. Eur J Cancer 43: 2495-505.
133. Geerts D, Schilderink N, Jorritsma G, Versteeg R (2003) The role of the MEIS homeobox genes in neuroblastoma. Cancer Lett 197: 87-92.
134. Wegner M (1999) From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 27: 1409-20.
135. Ferletta M, Uhrbom L, Olofsson T, Ponten F, Westermark B (2007) Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B-induced gliomagenesis. Mol Cancer Res 5: 891-7.
136. Vidal VP, Ortonne N, Schedl A (2008) SOX9 expression is a general marker of basal cell carcinoma and adnexal-related neoplasms. J Cutan Pathol 35: 373-9.
137. Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y (2008) SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer 98: 824-31.
138. Futaki S, Hayashi Y, Emoto T, Weber CN, Sekiguchi K (2004) Sox7 plays crucial roles in parietal endoderm differentiation in F9 embryonal carcinoma cells through regulating Gata-4 and Gata-6 expression. Mol Cell Biol 24: 10492-503.
139. Katoh M (2002) Expression of human SOX7 in normal tissues and tumors. Int J Mol Med 9: 363-8.
140. Guo L, Zhong D, Lau S, Liu X, Dong XY, et al. (2008) Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res 6: 1421-30.
141. Zhang Y, Rath N, Hannenhalli S, Wang Z, Cappola T, et al. (2007) GATA and Nkx factors synergistically regulate tissue-specific gene expression and development in vivo. Development 134: 189-198.
142. Ackerman KG, Herron BJ, Vargas SO, Huang H, Tevosian SG, et al. (2005) Fog2 is required for normal diaphragm and lung development in mice and humans. PLoS Genet 1: 58-65.
143. Ackerman KG, Wang J, Luo L, Fujiwara Y, Orkin SH, et al. (2007) Gata4 is necessary for normal pulmonary lobar development. Am J Respir Cell Mol Biol 36(4): 391-7.
144. Tsai FY, Orkin SH (1997) Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. Blood 89: 3636-43.
145. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, et al. (1991a) Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251: 1366-1370.
146. Matsumine A, Senda T, Baeg GH, Roy BC, Nakamura Y, et al. (1996b) MCC, a cytoplasmic protein that blocks cell cycle progression from the G0/G1 to S phase. J Biol Chem 271: 10341-10346.
147. Oreffo VI, Robinson S, You M, Wu MC, Malkinson AM (1998) Decreased expression of the adenomatous polyposis coli (Apc) and mutated in colorectal cancer (Mcc) genes in mouse lung neoplasia. Mol Carcinog 21: 37-49.
148. Fong KM, Zimmerman PV, Smith PJ (1995) Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. Cancer Res 55: 220-3.
149. Wu Q, Maniatis T (1999) A striking organization of a large family of human neural cadherin-like cell adhesion genes. Cell 97: 779-790.
150. Fisher A, Caudy M (1998) The function of hairy-related bHLH repressor proteins in cell fate decisions. Bioassays 21: 298-306.
151. Henderson AM, Wang SJ, Taylor AC, Aitkenhead M, Hughes CC (2001) The Basic Helix-Loop-Helix Transcription Factor HESR1 Regulates Endothelial Cell Tube Formation. J Biol Chem 276: 6169-6176.
152. Huang Q, Raya A, DeJesus P, Chao SH, Quon KC, et al. (2004) Identification of p53 regulators by genome-wide functional analysis. Proc Natl Acad Sci 101: 3456-61.
153. Simone NL, Bonner RF, Gillespie JW, Emmert-Buck MR, Liotta LA (1998) Laser-Capture microdissection: opening the microscopic frontier to molecular analysis. TIG 14: 272-276.
154. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-76.
155. Reck M, Crino L (2008) Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. J Lung Cancer [Epub ahead of print] PMID: 18579254.
156. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, et al. (2008) VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 14: 7871-7.
157. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, et al. (2003) Mechanism of p38 MAP kinase activation in vivo. Genes Dev 17: 1969-78.
158. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, et al. (2003) Farnesyltransferase inhibitors: An overview of the results of preclinical and clinical investigations. Cancer Res 63: 5656-5668.
159. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
160. Rahmani M, Davis EM, Bauer C, Dent P, Grant S (2005) Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 280: 35217-35227.
161. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, et al. (2008) Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 22: 808-818.
162. Liu L, Cao Y, Chen C, Zhang X, McNabola A, et al. (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858.
163. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, et al. (2005) The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24: 6861-6869.
164. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, et al. (2007) Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 67: 9443-9454.
165. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505-2512.
166. Morin PJ (2005) Claudin proteins in human cancer: Promising new targets for diagnosis and therapy. Cancer Res 65: 9603-9606.
167. Li D, Mrsny RJ (2000) Oncogenic Raf-1 disrupts epithelial tight junctions via downregulation of occluding. J Cell Biol 148: 791-800.
168. Bakre MM, Zhu Y, Yin H, Burton DW, Terkeltaub R, et al. (2002) Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. Nature Med 8: 995-1003.
169. Hsu SJ, Nagase H, Balmain A (2004) Identification of Fetuin-B as a member of a cystatin-like gene family on mouse chromosome 16 with tumor suppressor activity. Genome 47: 931-46.
170. Hamm A, Veeck J, Bektas N, Wild PJ, Hartmann A, et al. (2008) Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer 8: 25.
171. Mbikay M, Sirois F, Yao J, Seidah NG, Chrétien M (1997) Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer 75: 1509-14.
172. Anglim PP, Galler JS, Koss MN, Hagen JA, Turla S, et al. (2008) Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer 7: 62.
173. Hiesberger T, Shao X, Gourley E, Reimann A, Pontoglio M, et al. (2005)
174. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular permeability and angiogenesis. Am J Pathol 146: 1029-1039.
175. Achen MG, Williams RA, Baldwin ME, Lai P, Roufail S, et al. (2002) The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer. Growth Factors 20: 99-107.
176. Mansson-Broberg A, Siddiqui AJ, Genander M, Grinnemo KH, Hao X, et al. (2008) Modulation of ephrinB2 leads to increased angiogenesis in ischemic myocardium and endothelial cell proliferation. Biochem Biophys Res Commun 373: 355-9.
177. Suzuki Y, Montagne K, Nishihara A, Watabe T, Miyazono K (2008) BMPs promote proliferation and migration of endothelial cells via stimulation of VEGF-A/VEGFR2 and angiopoietin-1/Tie2 signalling. J Biochem 143: 199-206.
178. Sharff KA, Song WX, Luo X, Tang N, Luo J, et al. (2009) Hey1 basic helix-loop-helix protein plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. J biol Chem 284: 649-59.
179. Fischer A, Steidl C, Wagner TU, Lang E, Jakob PM, et al. (2007) Combined loss of Hey1 and HeyL causes congenital heart defects because of impaired epithelial to mesenchymal transition. Circ Res 100: 856-63.
180. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, et al. (2000) Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 92: 1355-7.
181. Ma LL, Sun WJ, Wang Zh, Zh GY, Li P, et al. (2006) Effects of silencing of mutant p53 gene in human lung adenocarcinoma cell line Anip973. J Exp Clin Cancer Res 25: 585-92.
182. Zhou Y, Lim KC, Onodera K, Takahashi S, Ohta J, et al. (1998) Rescue of the embryonic lethal hematopoietic defect reveals a critical role for GATA-2 in urogenital development. EMBO J 17: 6689-700.
183. George KM, Leonard MW, Roth ME, Lieuw KH, Kioussis D, et al. (1994) Embryonic expression and cloning of the murine GATA-3 gene. Development 120: 2673-86.
184. Yamada Y, Pannell R, Forster A, Rabbitts TH (2000) The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice. Proc Nat Acad Sci 97: 320-324.
185. Wu J, Bohanan CS, Neumann JC, Lingrel JB (2008) KLF2 transcription factor modulates blood vessel maturation through smooth muscle cell migration. J Biol Chem 283: 3942-50.
186. Cao H, Mok A, Miskie B, Hegele RA (2001) Single-nucleotide polymorphisms of the proprotein convertase subtilisin/kexin type 5 (PCSK5) gene. J Hum Genet 46: 730-732.
187. Chang HYS, Sneddon JB, Alizadeh AA, Sood R, West RB, et al. (2004) Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol 2: 206-14.
188. Shimizu T, Wolfe LS (1990) Arachidonic acid cascade and signal transduction. J Neurochem 55: 1-15.
189. Sales KJ, List T, Boddy SC, Williams ARW, Anderson RA, et al. (2005) A Novel Angiogenic Role for Prostaglandin F2-FP Receptor Interaction in Human Endometrial Adenocarcinomas. Cancer Research 65: 7707-7716.
190. Wright JK, Botha JH, Naidoo S (2008) Influence of the kallikrein-kinin system on prostate and breast tumour angiogenesis. Tumour Biol 29: 130-6.
191. Krupp M, Weinmann A, Galle PR, Teufel A (2006) Actin binding LIM protein 3 (abLIM3). Int J Mol Med 17: 129-33.
192. Caloca MJ, Zugaza LJ, Vicente-Manzanares M, Sánchez-Madrid F, Bustelo XR (2004) F-actin-dependent Translocation of the Rap1 GDP/GTP Exchange Factor RasGRP2. Biol Chem 279: 20435-20446.
193. Wikström P, Lissbrant IF, Stattin P, Egevad L, Bergh A (2002) Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51: 268-75.
194. Xie Y, Chan H, Fan J, Chen Y, Young J, et al. (2007) Involvement of visinin-like protein-1 (VSNL-1) in regulating proliferative and invasive properties of neuroblastoma. Carcinogenesis 28: 2122-30.
195. Kitwareewan S, Blumen S, Sekula D, Bissonnette RP, Lamph WW, et al. (2008) G0S2 is an all-trans-retinoic acid target gene. Int J Oncol 33: 397-404.
196. Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, et al. (2208) Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer. Clin Cancer Res 14: 6924-32.
197. Diehl D, Hessel E, Oesterle D, Renner-Mü_ller I, Elmlinger M, et al. (2009) IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis. Int J Cancer 124: 2220-5.
198. Liang S, Wei FY, Wu YM, Tanabe K, Abe T, et al. (2007) Major Cdk5-dependent phosphorylation sites of amphiphysin 1 are implicated in the regulation of the membrane binding and endocytosis. J Neurochem 102: 1466-76.
199. Bhattacharya R, Frankfurter A, Cabral F (2008) A minor beta-tubulin essential for mammalian cell proliferation. Cell Motil Cytoskeleton 65: 708-20.
200. Ulich TR, Yi ES, Longmuir K, Yin S, Biltz R, et al. (1994) Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. J Clin Invest 93: 1298-1306.
201. Ulrich K, Stern M, Goddard ME, Wiliams J, Zhu J, et al. (2005) Keratinocyte growth factor therapy in murine oleic acid-induced acute lung injury. Am J Physiol Öung Cell Mol Physiol 288: L1179-92.
202. Chelly N, Mouhieddine-Gueddiche OB, Barlier-Mur AM, Chailley-Heu B, Bourbon JR (1999) Keratinocyte growth factor enhances maturation of fetal rat lung type II cells. Am J Respir Cell Mol Biol 20: 423-432.
203. Yamayoshi T, Nagayasu T, Matsumoto K, Abo T, Hishikawa Y, et al. (2004) Expression of keratinocyte growth factor/fibroblast growth factor-7 and its receptor in human lung cancer: correlation with tumour proliferative activity and patient prognosis. J Pathol 204: 110-8.
204. Drimal J, Drimal D (2000) Enhanced endothelin ETB receptor down-regulation in human tumor cells. Eur J Pharmacol 396: 19-22.
205. Kaplan- Albuquerque N, Bogaert YE, van Putten V, Weiser-Evans MC, Nemenoff RA (2005) Patterns of Gene Expression Differentially Regulated by Platelet-derived Growth Factor and Hypertrophic Stimuli in Vascular Smooth Muscle Cells. J Biol Chem 280: 19966-19976.
206. Dai Z, Popkie AP, Zhu WG, Timmers CD, Raval A, et al. (2004) Bone morphogenetic protein 3B silencing in non-small-cell lung cancer. Oncogene 23: 3521-3529.
207. Kraunz KS, Nelson HH, Liu M, Wiencke JK, Kelsey KT (2005) Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signalling pathways in lung cancer. Br J Cancer 93: 949-52.
208. Ren R, Charles PC, Zhang C, Wu Y, Wang H, et al. (2007) Gene expression profiles identify a role for cyclooxygenase 2-dependent prostanoid generation in BMP6-induced angiogenic responses. Blood 109: 2847-2853.
209. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, et al. (2003) WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201: 204-12.
210. You L, He B, Xu Z, Uematsu K, Mazieres J, et al. (2004) Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 23: 6170-4.
211. Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J, et al. (2008) Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci 99: 1326-33.
212. Nomoto K, Tomita N, Miyake M, Xhu DB, LoGerfo PR, et al. (1995) Expression of phospholipases 1, β1, and 1 in primary human colon carcinomas and colon carcinoma cell lines. Mol Carcinog 12: 146-52.
213. Shepard CR, Kassis J, Whaley DL, Kim HG, Wells A (2007) PLC contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene 26: 3020-6.
214. Kohno T, Otsuka T, Takano H, Yamamoto T, Hamaguchi M, et al. (1995) Identification of a novel phospholipase C family gene at chromosome 2q33 that is homozygously deleted in human small cell lung carcinoma. Hum Mol Genet 4: 667-74.
215. Liu Y, Wang B, Wang J, Wan W, Sun R, et al. (2009) Down-regulation of PKCzeta expression inhibits chemotaxis signal transduction in human lung cancer cells. Lung Cancer 63: 210-8.
216. Choi PM, Tchou-wong KM, Weinstein IB (1990) Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression. Mol Cell Biol 10: 4650-4657.
217. Veninga H, Becker S, Hoek RM, Wobus M, Wandel E, et al. (2008) Analysis of CD97 expression and manipulation: antibody treatment but not gene targeting curtails granulocyte migration. J Immunol 181: 6574-83.
218. Perez OD, Kinoshita S, Hitoshi Y, Payan DG, Kitamura T, et al. (2002) Activation of the PKB/AKT pathway by ICAM-2. Immunity 16: 51-65.
219. Tanaka H, Yashiro M, Sunami T, Sakate Y, Kosaka K, et al. (2004) ICAM-2 gene therapy for peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res 10: 4885-92.
220. Banerjee S, Dhar G, Haque I, Kambhampati S, Mehta S, et al. (2008) CCN5/ WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res 68: 7606-12.
221. Shen R, Ouyang YB, Qu CK, Alonso A, Sperzel L, et al. (2002) Grap negatively regulates T-cell receptor-elicited lymphocyte proliferation and interleukin-2 induction. Mol Cell Biol 22: 3230-6.
222. Ueda S, Mizuki M, Ikeda H, Tsujimura T, Matsumura I, et al. (2002) Critical roles of c-Kit tyrosine residues 567 and 719 in stem cell factor-induced chemotaxis: contribution of src family kinase and PI3-kinase on calcium mobilization and cell migration. Blood 99: 3342-3349.
223. Roskoski R (2005) Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 337: 1-13.
224. Micke P, Hengstler JG, Albrecht H, Faldum A, Bittinger F, et al. (2004) c-kit Expression in Adenocarcinomas of the Lung. Tumor Biology 25: 235-242.
225. Zakut R, Perlis R, Eliyahu S, Yarden Y, Givol D, et al. (1993) KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 8: 2221-2229.
226. Tonary AM, Macdonald EA, Faught W, Senterman MK, Vanderhyden BC (2000) Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer 89: 242-250.
227. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198.
228. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. PNAS 98: 5116-5121.